Aurobindo Pharma slips 5% after detailed USFDA observations to unit 3

USFDA observed that responsibilities and procedures applicable to the quality control unit are not in writing and fully followed

Aurobindo Pharma shares fell nearly 5 percent intraday on June 3 after detailed USFDA observations for company's unit-3.

The stock was quoting at Rs 645.30, down Rs 27.45, or 4.08 percent on the BSE, at 1332 hours IST.

CNBC-TV18 accessed Form 483 issued by US Food and Drug Administration to company's unit-3 after inspection during May 13-24, 2019.

The unit-3 is a multi-product oral dosage form facility for non-cephalosporins and non-beta-lactams.

The unit had received 10 observations which are:

1) Responsibilities and procedures applicable to the quality control unit are not in writing and fully followed;

2) Sample which is representative of each lot in each shipment of each active ingredient is not appropriately identified and retained;

3) Written procedures are not followed for cleaning and maintenance of equipment;

4) Lab records do not include complete data derived from all tests, examinations;

5) Written records of investigations into unexplained discrepancies do not always include conclusions, follow up;

6) A written record of investigations of drug complaint does not include findings of the investigation and follow up;

7) Appropriate controls not exercised over computers or related systems to assure changes are instituted only by authorized personnel;

8) Back up data is not assured from alteration, erasure or loss;

9) Drug product expiration dates not related to storage conditions stated on labeling;10) Buildings used for drug products do not have suitable construction.

For taking 2 days free trial and Stock Market Tips with more than 90% accuracy click here MCX Tips